🇺🇸 Tropicamide Ophthalmic in United States

54 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Effect Prolonged — 10 reports (18.52%)
  2. Mydriasis — 9 reports (16.67%)
  3. Vision Blurred — 7 reports (12.96%)
  4. Drug Ineffective — 5 reports (9.26%)
  5. Eye Irritation — 5 reports (9.26%)
  6. Product Quality Issue — 5 reports (9.26%)
  7. Eye Pain — 4 reports (7.41%)
  8. Condition Aggravated — 3 reports (5.56%)
  9. Headache — 3 reports (5.56%)
  10. Pupil Fixed — 3 reports (5.56%)

Source database →

Other Ophthalmology approved in United States

Frequently asked questions

Is Tropicamide Ophthalmic approved in United States?

Tropicamide Ophthalmic does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tropicamide Ophthalmic in United States?

Semnan University of Medical Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.